leadf
logo-loader
viewZelira Therapeutics Ltd

Ilera Healthcare deal is 'one piece of the puzzle' for Zelda Therapeutics in 'globalising product'

Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) managing director Dr Richard Hopkins speaks to Proactive Investors about the medical cannabis researcher's binding heads of agreement (HoA) with US-based medicinal cannabis company Ilera Healthcare LLC.

The deal complements a number of agreements that Zelda has in place with international partners, and more such deals are set to be announced this year.

Hopkins  explains, "We've got access to in excess of 110,000 registered medicinal cannabis patients at the moment, which is in excess of 30 times larger than the whole Australian market; so this is our approach to globalising our product... Putting in that framework that allows us to rapidly commercialise the outcomes from our clinical trials."

Quick facts: Zelira Therapeutics Ltd

Price: 0.089 AUD

ASX:ZLD
Market: ASX
Market Cap: $105.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

3 weeks, 4 days ago

2 min read